{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:34:37Z","timestamp":1793392477453,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019645","name":"Tongmyong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002457","name":"Chosun University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ibroneuroreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IBRO Neuroscience Reports"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ibneur.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T20:31:07Z","timestamp":1679689867000},"page":"366-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Investigating the symptomatic and morphological changes in the brain based on pre and post-treatment: A critical review from clinical to neuroimaging studies on schizophrenia"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-8888","authenticated-orcid":false,"given":"Indranath","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-9919","authenticated-orcid":false,"given":"Shilpa","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ibneur.2023.03.008_bib1","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1038\/npp.2015.90","article-title":"Progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine treatment","volume":"40","author":"Ahmed","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ibneur.2023.03.008_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/schbul\/sbn029","article-title":"Clinical course and outcome of schizophrenia in a predominantly treatment-naive cohort in rural Ethiopia","volume":"35","author":"Alem","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ibneur.2023.03.008_bib3","series-title":"Schizophrenia and other psychotic disorders","first-page":"89","article-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.ibneur.2023.03.008_bib4","unstructured":"Astrup C., Noreik K.: Functional Psychoses: Diagnostic and Prognostic Models. Springfield, Ill, Charles. Thomas, 196634."},{"key":"10.1016\/j.ibneur.2023.03.008_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archpsyc.58.1.33","article-title":"Volumes of brain structures in twins discordant for schizophrenia","volume":"58","author":"Baar\u00e9","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.ibneur.2023.03.008_bib6","doi-asserted-by":"crossref","DOI":"10.48129\/kjs.v48i2.9264","article-title":"Role of neurotransmitters in schizophrenia: A comprehensive study","volume":"48","author":"Bansal","year":"2021","journal-title":"Kuwait J. Sci."},{"key":"10.1016\/j.ibneur.2023.03.008_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.schres.2011.06.029","article-title":"Long acting injection vs oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory","volume":"132","author":"Bartzokis","year":"2011","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.ibneur.2023.03.008_bib8","unstructured":"Beauregard M. Functional neuroimaging studies of the effects of psychotherapy. Dialogues in Clinical Neuroscience. 2022 Apr 1."},{"key":"10.1016\/j.ibneur.2023.03.008_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/JCP.0b013e31820e3f58","article-title":"Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia","volume":"31","author":"Boonstra","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"36","key":"10.1016\/j.ibneur.2023.03.008_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommenda-tions and summary statements","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.ibneur.2023.03.008_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0920-9964(97)00076-5","article-title":"Functional brain imaging and aging in schizophrenia","volume":"27","author":"Buchsbaum","year":"1997","journal-title":"Schizophr. Res."},{"issue":"33","key":"10.1016\/j.ibneur.2023.03.008_bib12","doi-asserted-by":"crossref","first-page":"24757","DOI":"10.1007\/s11042-020-09183-z","article-title":"Impact of ageing on the brain regions of the schizophrenia patients: an fMRI study using evolutionary approach","volume":"79","author":"Chatterjee","year":"2020","journal-title":"Multimed. Tools Appl."},{"key":"10.1016\/j.ibneur.2023.03.008_bib13","first-page":"7","article-title":"Mean deviation based identification of activated voxels from time-series fMRI data of schizophrenia patients","author":"Chatterjee","year":"2018","journal-title":"F1000Research"},{"issue":"4","key":"10.1016\/j.ibneur.2023.03.008_bib14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4088\/JCP.18nr12554","article-title":"Patches: established and emerging transdermal treatments in psychiatry","volume":"80","author":"Citrome","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib16","series-title":"1Pharmacotherapy: A Pathophysiologic Approach","first-page":"1019","article-title":"Schizophrenia","author":"Crismon","year":"2014"},{"issue":"12","key":"10.1016\/j.ibneur.2023.03.008_bib17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","article-title":"Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia","volume":"174","author":"Davidson","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.pnpbp.2005.08.019","article-title":"Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia?","volume":"30","author":"Dean","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.ibneur.2023.03.008_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-4927(99)00033-5","article-title":"Defining the course of brain structural change and plasticity in schizophrenia","volume":"92","author":"DeLisi","year":"1999","journal-title":"Psychiatry Res.: Neuroimag."},{"issue":"8","key":"10.1016\/j.ibneur.2023.03.008_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/NMD.0b013e318225ee78","article-title":"Evidence-based psychotherapy for schizophrenia: 2011 update","volume":"199","author":"Dickerson","year":"2011","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.ibneur.2023.03.008_bib21","unstructured":"ENHANCE-1). clinicaltrials.gov\/ct2\/show\/NCT02970292. Updated August 29, 2019. Accessed November 22, 2019."},{"issue":"2","key":"10.1016\/j.ibneur.2023.03.008_bib22","first-page":"130","article-title":"New schizophrenia treatments address unmet clinical needs","volume":"42","author":"Fellner","year":"2017","journal-title":"P T."},{"key":"10.1016\/j.ibneur.2023.03.008_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2012.05.008","article-title":"Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies","volume":"52","author":"Fu","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ibneur.2023.03.008_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2013.06.025","article-title":"Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naive first-episode psychosis patients","volume":"149","author":"Goghari","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ibneur.2023.03.008_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Grilly","year":"2007","journal-title":"Hist. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib27","doi-asserted-by":"crossref","first-page":"h2435","DOI":"10.1136\/bmj.h2435","article-title":"Does long term use of psychi-atric drugs cause more harm than good?","volume":"350","author":"G\u00f8tzsche","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ibneur.2023.03.008_bib28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/schbul\/sbs118","article-title":"Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects","volume":"39","author":"Haijma","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ibneur.2023.03.008_bib29","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.npp.1301347","article-title":"Focal gray matter changes in schizophrenia across the course of the illness:A 5-year follow-up study","volume":"32","author":"Van Haren","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ibneur.2023.03.008_bib30","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1017\/S0033291714000610","article-title":"Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A20-year multi-follow-up study","volume":"44","author":"Harrow","year":"2014","journal-title":"Psychol. Med"},{"issue":"4","key":"10.1016\/j.ibneur.2023.03.008_bib31","first-page":"432","article-title":"Functional brain mapping of psychopathology","volume":"72","author":"Honey","year":"2002","journal-title":"J. Neurol., Neurosurg. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","article-title":"Long term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia","volume":"68","author":"Ho","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","article-title":"Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia","volume":"68","author":"Ho","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib34","series-title":"Therapies announces positive top-line results from the first phase 3 trial of ITI-007 in patients with schizophrenia and confirms the unique pharmacology of ITI-007 in a separate positron emission tomography study [news release]","author":"Intra-Cellular","year":"2015"},{"issue":"7","key":"10.1016\/j.ibneur.2023.03.008_bib35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","article-title":"Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia","volume":"52","author":"Kapur","year":"2001","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.ibneur.2023.03.008_bib37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.ibneur.2023.03.008_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/0963721410377601","article-title":"Structural and Functional Brain Abnormalities in Schizophrenia","volume":"vol. 19","author":"Karlsgodt","year":"2010","journal-title":"Curr. Dir. Psychol. Sci."},{"issue":"3","key":"10.1016\/j.ibneur.2023.03.008_bib39","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11753","article-title":"Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial","volume":"79","author":"Keefe","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.ibneur.2023.03.008_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.schres.2012.11.012","article-title":"A multimodal approach to investigate biomarkers for psychosis in a clinical setting: the integrative neuroimaging studies in schizophrenia targeting for early intervention and prevention (IN-STEP) project","volume":"143","author":"Koike","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ibneur.2023.03.008_bib41","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.npp.1301233","article-title":"Effect of chronic exposure to antipsychotic medication on cell numbers inthe parietal cortex of macaque monkeys","volume":"32","author":"Konopaske","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"suppl 1","key":"10.1016\/j.ibneur.2023.03.008_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"key":"10.1016\/j.ibneur.2023.03.008_bib43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.schres.2005.07.021","article-title":"Never-treated patients with schizophrenia in the developing country of Bali","volume":"79","author":"Kurihara","year":"2005","journal-title":"Schizophr. Res"},{"issue":"1","key":"10.1016\/j.ibneur.2023.03.008_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.npp.1300312","article-title":"Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex","volume":"29","author":"Lahti","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.ibneur.2023.03.008_bib45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","article-title":"Increased dopamine transmission in schizophrenia: relationship to illness phases","volume":"46","author":"Laruelle","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib46","series-title":"Clinical Handbook of Schizophrenia","first-page":"3","article-title":"History of Schizophrenia as a Psychiatric Disorder","author":"Lavretsky","year":"2008"},{"key":"10.1016\/j.ibneur.2023.03.008_bib47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1192\/bjp.172.2.110","article-title":"Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies","volume":"172","author":"Lawrie","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"suppl 2","key":"10.1016\/j.ibneur.2023.03.008_bib48","first-page":"1","article-title":"American Psychiatric Association Practice Guidelines; Work Group on Schizophrenia. Practice guideline for the treatment of patients with schizophrenia","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib49","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib50","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ibneur.2023.03.008_bib51","first-page":"136","article-title":"The cerebral cortex: acase for a common site of action of antipsychotics. Trends Phar-macol","volume":"19","author":"Lidow","year":"1998","journal-title":"Sci"},{"key":"10.1016\/j.ibneur.2023.03.008_bib52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0006-3223(01)01067-8","article-title":"Longitudinal study of brain morphology in first episode schizophrenia","volume":"49","author":"Lieberman","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib53","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. JMed"},{"issue":"7","key":"10.1016\/j.ibneur.2023.03.008_bib54","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4088\/JCP.08m04221","article-title":"Medication non-adherence and treatment outcomes in patients with schizophrenia or schizoaffective disorder with suboptimal prior response","volume":"70","author":"Lindenmayer","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10401230591002002","article-title":"History and the discovery and clinical introduction of chlorpromazine","volume":"17","author":"Lo'pez-Mun\u203eoz","year":"2005","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib56","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2147\/NDT.S197225","article-title":"Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia","volume":"15","author":"Mathews","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ibneur.2023.03.008_bib57","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archpsyc.1981.01780320056006","article-title":"Schizophrenia: a follow-up study of the results of five forms of treatment","volume":"38","author":"May","year":"1981","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.ibneur.2023.03.008_bib58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archpsyc.61.2.134","article-title":"Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F] fluorodopa study","volume":"61","author":"McGowan","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.ibneur.2023.03.008_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tips.2007.11.005","article-title":"Functional neuroimaging in schizophrenia: diagnosis and drug discovery","volume":"29","author":"McGuire","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ibneur.2023.03.008_bib60","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.biopsych.2010.11.003","article-title":"Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis","volume":"69","author":"McIntosh","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.ibneur.2023.03.008_bib61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ibneur.2023.03.008_bib62","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/schbul\/sbn131","article-title":"Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia","volume":"36","author":"Meyer","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ibneur.2023.03.008_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.schres.2005.07.031","article-title":"Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia","volume":"80","author":"Molina","year":"2005","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.ibneur.2023.03.008_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00421933","article-title":"Pharmacology of neuroleptics upon repeated administration","volume":"34","author":"Moller Nielsen","year":"1974","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.ibneur.2023.03.008_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001861","article-title":"Antipsychotic maintenance treatment: time to re-think?","volume":"12","author":"Moncrieff","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.ibneur.2023.03.008_bib66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia","volume":"8","author":"Morken","year":"2008","journal-title":"BMC Psychiatry"},{"issue":"5","key":"10.1016\/j.ibneur.2023.03.008_bib67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2215-0366(15)00540-4","article-title":"Brain-imaging studies of treatment-resistant schizophrenia: a systematic review","volume":"3","author":"Mouchlianitis","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib68","first-page":"381","article-title":"A prospective longitudinal investigation of cortical thickness and gyrification in schizophrenia","volume":"65","author":"Nelson","year":"2020","journal-title":"Canad. J. Psychiatry Rev. Canad. Psychiatr."},{"key":"10.1016\/j.ibneur.2023.03.008_bib69","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1176\/ajp.120.8.772","article-title":"Pattern of discharge from Norwegian psychiatric hospitals before and after the introduction of the psychotropic drugs","volume":"120","author":"Odegard","year":"1964","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biopsych.2011.01.032","article-title":"Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies","volume":"70","author":"Olabi","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"9690","key":"10.1016\/j.ibneur.2023.03.008_bib71","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"\"Schizophrenia\"","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ibneur.2023.03.008_bib72","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.2174\/156802612805289881","article-title":"The concept of salience network dysfunction in schizophrenia: from neuroimaging observations to therapeutic opportunities","volume":"12","author":"Palaniyappan","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"issue":"10","key":"10.1016\/j.ibneur.2023.03.008_bib73","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.biopsych.2013.01.017","article-title":"Brain effects of cognitive remediation therapy in schizophrenia: a structural and functional neuroimaging study","volume":"73","author":"Penad\u00e9s","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib74","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1176\/appi.ajp.162.10.1785","article-title":"Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: acritical review and meta-analysis","volume":"162","author":"Perkins","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archpsyc.1964.01720260031004","article-title":"First admitted schizophrenics in drug era: follow-up of Anoka schizophrenic cohort, 1956-1958","volume":"11","author":"Peterson","year":"1964","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.ibneur.2023.03.008_bib76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1176\/appi.ajp.2007.07071066","article-title":"Medication effects in neuroimaging studies of bipolar disorder","volume":"165","author":"Phillips","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib77","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1192\/bjp.113.505.1345","article-title":"Prognosis of schizophrenia before and after pharmacotherapy, I: short term outcome","volume":"113","author":"Pritchard","year":"1967","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib78","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1192\/bjp.bp.114.157685","article-title":"Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China","volume":"207","author":"Ran","year":"2015","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ibneur.2023.03.008_bib79","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight","volume":"18","author":"Revel","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.ibneur.2023.03.008_bib80","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1586\/14737175.8.7.1067","article-title":"Psychoeducation for patients with schizophrenia and their families","volume":"8","author":"Rummel-Kluge","year":"2008","journal-title":"Exp. Rev. Neurother."},{"issue":"6","key":"10.1016\/j.ibneur.2023.03.008_bib81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/14728222.2018.1480723","article-title":"Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases","volume":"22","author":"Schwartz","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ibneur.2023.03.008_bib82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0006-3223(98)00281-9","article-title":"The reduced neuropil hypothesis: a circuit based model of schizophrenia","volume":"45","author":"Selemon","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.ibneur.2023.03.008_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00163-3","article-title":"A review of MRI findings in schizophrenia","volume":"49","author":"Shenton","year":"2001","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.ibneur.2023.03.008_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/14737175.6.1.57","article-title":"Antipsychotic drug action: targets for drug discovery with neurochemical imaging","volume":"6","author":"Stone","year":"2006","journal-title":"Expert Rev. Neurother."},{"issue":"11","key":"10.1016\/j.ibneur.2023.03.008_bib85","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2018.09.002","article-title":"Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia","volume":"40","author":"Sun","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ibneur.2023.03.008_bib86","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.38881.382755.2F","article-title":"Effectiveness of anti-psychotic treatments in a nationwide cohort of patients in com-munity care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study","volume":"333","author":"Tiihonen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ibneur.2023.03.008_bib87","unstructured":"U.S. FDA approves Secuado (asenapine) transdermal system, the first-and-only transdermal patch for the treatment of adults with schizophrenia [news release]. Miami, FL, and Jersey City, NJ: Noven Pharmaceuticals, Inc; October 15, 2019."},{"issue":"suppl 1","key":"10.1016\/j.ibneur.2023.03.008_bib88","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1093\/schbul\/sby018.831","article-title":"S44. Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching study","volume":"44","author":"Vanover","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ibneur.2023.03.008_bib89","first-page":"936","article-title":"Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation","volume":"69","author":"Vernon","year":"2011","journal-title":"BiolPsychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib90","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.biopsych.2015.02.008","article-title":"The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies","volume":"78","author":"Vita","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib91","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jamapsychiatry.2020.0036","article-title":"Effects of antipsychotic medication on brain structure in patients with major depressive disorder and psychotic features: neuroimaging findings in the context of a randomized placebo-controlled clinical trial","volume":"77","author":"Voineskos","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib92","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1586\/ern.11.76","article-title":"Understanding aberrant white matter development in schizophrenia: an avenue for therapy","volume":"11","author":"Walterfang","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ibneur.2023.03.008_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0306-9877(03)00293-7","article-title":"The case against antipsychotic drugs: a 50-year recordof doing more harm than good","volume":"62","author":"Whitaker","year":"2004","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.ibneur.2023.03.008_bib94","unstructured":"Whitaker R.: The Case Against Antipsychotics: A Review of Their Long-Term Side Effects. Cambridge, Mass, Mad in America Foundation, 2016."},{"key":"10.1016\/j.ibneur.2023.03.008_bib95","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/ajp.157.1.16","article-title":"Meta-analysis of regional brain volumes in schizophrenia","volume":"157","author":"Wright","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib96","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy:long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ibneur.2023.03.008_bib97","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4088\/JCP.v68n0502","article-title":"Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome","volume":"68","author":"Wunderink","year":"2007","journal-title":"J. Clin. Psychiatry"}],"container-title":["IBRO Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242123000258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242123000258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:14:33Z","timestamp":1757405673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667242123000258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":97,"alternative-id":["S2667242123000258"],"URL":"https:\/\/doi.org\/10.1016\/j.ibneur.2023.03.008","relation":{},"ISSN":["2667-2421"],"issn-type":[{"value":"2667-2421","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the symptomatic and morphological changes in the brain based on pre and post-treatment: A critical review from clinical to neuroimaging studies on schizophrenia","name":"articletitle","label":"Article Title"},{"value":"IBRO Neuroscience Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ibneur.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Brain Research Organization.","name":"copyright","label":"Copyright"}]}}